tiprankstipranks
CG Oncology, Inc. (CGON)
NASDAQ:CGON
US Market
CGON
CG Oncology, Inc.
RESEARCH TOOLSreports
Want to see CGON full AI Analyst Report?

CG Oncology, Inc. (CGON) Stock Forecast & Price Target

340 Followers
See the Price Targets and Ratings of:

CGON Analyst Ratings

Strong Buy
14Ratings
Strong Buy
13 Buy
1 Hold
0 Sell
Based on 14 analysts giving stock ratings to
CG
Oncology, Inc.
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CGON Stock 12 Month Forecast

Average Price Target

$91.55
▲(24.67% Upside)
Based on 14 Wall Street analysts offering 12 month price targets for CG Oncology, Inc. in the last 3 months. The average price target is $91.55 with a high forecast of $108.00 and a low forecast of $80.00. The average price target represents a 24.67% change from the last price of $73.43.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"25":"$25","46":"$46","67":"$67","88":"$88","109":"$109"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":108,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$108.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":91.54545454545455,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$91.55</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":80,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$80.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[25,46,67,88,109],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,59.23,62.981538461538456,66.73307692307692,70.48461538461538,74.23615384615384,77.9876923076923,81.73923076923077,85.49076923076923,89.24230769230769,92.99384615384615,96.74538461538461,100.49692307692308,104.24846153846153,{"y":108,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,59.23,61.715804195804196,64.20160839160839,66.68741258741258,69.17321678321679,71.65902097902098,74.14482517482517,76.63062937062938,79.11643356643357,81.60223776223776,84.08804195804196,86.57384615384615,89.05965034965035,{"y":91.54545454545455,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,59.23,60.8276923076923,62.425384615384615,64.02307692307693,65.62076923076923,67.21846153846154,68.81615384615384,70.41384615384615,72.01153846153846,73.60923076923076,75.20692307692308,76.80461538461539,78.40230769230769,{"y":80,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":26.59,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.35,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.31,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.46,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.46,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.27,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.25,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.52,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.34,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.76,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.79,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.27,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.23,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$108.00Average Price Target$91.55Lowest Price Target$80.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
RBC Capital Analyst forecast on CGON
Leonid Timashev
RBC Capital
RBC Capital
$81
Buy
10.31%
Upside
Reiterated
06/30/26
Analysts Offer Insights on Healthcare Companies: CG Oncology, Inc. (NASDAQ: CGON), Alnylam Pharma (NASDAQ: ALNY) and Connect Biopharma Holdings (NASDAQ: CNTB)
Piper Sandler Analyst forecast on CGON
Kelsey Goodwin
Piper Sandler
Piper Sandler
$82
Buy
11.67%
Upside
Reiterated
06/23/26
Analysts Offer Insights on Healthcare Companies: CG Oncology, Inc. (NASDAQ: CGON), Natera (NASDAQ: NTRA) and Pfizer (NYSE: PFE)
JonesTrading Analyst forecast on CGON
Boris Peaker
JonesTrading
JonesTrading
$85
Buy
15.76%
Upside
Reiterated
06/16/26
Analysts Are Bullish on These Healthcare Stocks: PepGen Inc. (PEPG), CG Oncology, Inc. (CGON)
Truist Financial Analyst forecast on CGON
Gregory Renza
Truist Financial
Truist Financial
―
Buy
―
Reiterated
05/27/26
Analysts' Top Healthcare Picks: Spruce Biosciences (SPRB), CG Oncology, Inc. (CGON)
Bank of America Securities Analyst forecast on CGON
Alec Stranahan
Bank of America Securities
Bank of America Securities
$83→$87
Buy
18.48%
Upside
Reiterated
05/26/26
Alec Stranahan Reiterates Buy on CG Oncology, Lifts Price Target to $87 as Commercialization Plans Stay on Track
Wolfe Research Analyst forecast on CGON
Kalpit Patel
Wolfe Research
Wolfe Research
―
Hold
―
Reiterated
05/26/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Olema Pharmaceuticals (NASDAQ: OLMA) and CG Oncology, Inc. (NASDAQ: CGON)
H.C. Wainwright Analyst forecast on CGON
Andres Y. Maldonado
H.C. Wainwright
H.C. Wainwright
$100
Buy
36.18%
Upside
Reiterated
05/18/26
Buy Rating Reiterated on Robust Cretostimogene Data and De-Risked Phase 2 Program; $100 Price Target Maintained
Wedbush Analyst forecast on CGON
Robert Driscoll
Wedbush
Wedbush
$80
Buy
8.95%
Upside
Reiterated
05/18/26
Wedbush Remains a Buy on CG Oncology, Inc. (CGON)
LifeSci Capital Analyst forecast on CGON
Sam Slutsky
LifeSci Capital
LifeSci Capital
$108
Buy
47.08%
Upside
Reiterated
05/16/26
CG Oncology, Inc. (CGON) Receives a Rating Update from a Top Analyst
Morgan Stanley Analyst forecast on CGON
Sean Laaman
Morgan Stanley
Morgan Stanley
$93
Buy
26.65%
Upside
Reiterated
05/15/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Insulet (NASDAQ: PODD), ProKidney (NASDAQ: PROK) and CG Oncology, Inc. (NASDAQ: CGON)
TD Cowen Analyst forecast on CGON
Tyler Van Buren
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/11/26
CG Oncology Earns Buy Rating as Analyst Sees High Phase III Success Odds and Strengthened BLA Timeline for Lead Asset Creto
Cantor Fitzgerald Analyst forecast on CGON
Joshua Schimmer
Cantor Fitzgerald
Cantor Fitzgerald
$100→$105
Buy
42.99%
Upside
Reiterated
05/11/26
CG Oncology, Inc. (CGON) Gets a Buy from Cantor Fitzgerald
J.P. Morgan Analyst forecast on CGON
Brian Cheng
J.P. Morgan
J.P. Morgan
$91→$96
Buy
30.74%
Upside
Assigned
05/11/26
CG Oncology price target raised to $96 from $91 at JPMorganCG Oncology price target raised to $96 from $91 at JPMorgan
UBS Analyst forecast on CGON
David Dai
UBS
UBS
$90
Buy
22.57%
Upside
Reiterated
05/08/26
Analyst Reiterates Buy on CG Oncology, Maintains $90 Price Target Ahead of Key Cretostimogene Data Readouts
Guggenheim Analyst forecast on CGON
Bradley Canino
Guggenheim
Guggenheim
$90
Buy
22.57%
Upside
Reiterated
02/27/26
Guggenheim Sticks to Its Buy Rating for CG Oncology, Inc. (CGON)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
RBC Capital Analyst forecast on CGON
Leonid Timashev
RBC Capital
RBC Capital
$81
Buy
10.31%
Upside
Reiterated
06/30/26
Analysts Offer Insights on Healthcare Companies: CG Oncology, Inc. (NASDAQ: CGON), Alnylam Pharma (NASDAQ: ALNY) and Connect Biopharma Holdings (NASDAQ: CNTB)
Piper Sandler Analyst forecast on CGON
Kelsey Goodwin
Piper Sandler
Piper Sandler
$82
Buy
11.67%
Upside
Reiterated
06/23/26
Analysts Offer Insights on Healthcare Companies: CG Oncology, Inc. (NASDAQ: CGON), Natera (NASDAQ: NTRA) and Pfizer (NYSE: PFE)
JonesTrading Analyst forecast on CGON
Boris Peaker
JonesTrading
JonesTrading
$85
Buy
15.76%
Upside
Reiterated
06/16/26
Analysts Are Bullish on These Healthcare Stocks: PepGen Inc. (PEPG), CG Oncology, Inc. (CGON)
Truist Financial Analyst forecast on CGON
Gregory Renza
Truist Financial
Truist Financial
―
Buy
―
Reiterated
05/27/26
Analysts' Top Healthcare Picks: Spruce Biosciences (SPRB), CG Oncology, Inc. (CGON)
Bank of America Securities Analyst forecast on CGON
Alec Stranahan
Bank of America Securities
Bank of America Securities
$83→$87
Buy
18.48%
Upside
Reiterated
05/26/26
Alec Stranahan Reiterates Buy on CG Oncology, Lifts Price Target to $87 as Commercialization Plans Stay on Track
Wolfe Research Analyst forecast on CGON
Kalpit Patel
Wolfe Research
Wolfe Research
―
Hold
―
Reiterated
05/26/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Olema Pharmaceuticals (NASDAQ: OLMA) and CG Oncology, Inc. (NASDAQ: CGON)
H.C. Wainwright Analyst forecast on CGON
Andres Y. Maldonado
H.C. Wainwright
H.C. Wainwright
$100
Buy
36.18%
Upside
Reiterated
05/18/26
Buy Rating Reiterated on Robust Cretostimogene Data and De-Risked Phase 2 Program; $100 Price Target Maintained
Wedbush Analyst forecast on CGON
Robert Driscoll
Wedbush
Wedbush
$80
Buy
8.95%
Upside
Reiterated
05/18/26
Wedbush Remains a Buy on CG Oncology, Inc. (CGON)
LifeSci Capital Analyst forecast on CGON
Sam Slutsky
LifeSci Capital
LifeSci Capital
$108
Buy
47.08%
Upside
Reiterated
05/16/26
CG Oncology, Inc. (CGON) Receives a Rating Update from a Top Analyst
Morgan Stanley Analyst forecast on CGON
Sean Laaman
Morgan Stanley
Morgan Stanley
$93
Buy
26.65%
Upside
Reiterated
05/15/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Insulet (NASDAQ: PODD), ProKidney (NASDAQ: PROK) and CG Oncology, Inc. (NASDAQ: CGON)
TD Cowen Analyst forecast on CGON
Tyler Van Buren
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/11/26
CG Oncology Earns Buy Rating as Analyst Sees High Phase III Success Odds and Strengthened BLA Timeline for Lead Asset Creto
Cantor Fitzgerald Analyst forecast on CGON
Joshua Schimmer
Cantor Fitzgerald
Cantor Fitzgerald
$100→$105
Buy
42.99%
Upside
Reiterated
05/11/26
CG Oncology, Inc. (CGON) Gets a Buy from Cantor Fitzgerald
J.P. Morgan Analyst forecast on CGON
Brian Cheng
J.P. Morgan
J.P. Morgan
$91→$96
Buy
30.74%
Upside
Assigned
05/11/26
CG Oncology price target raised to $96 from $91 at JPMorganCG Oncology price target raised to $96 from $91 at JPMorgan
UBS Analyst forecast on CGON
David Dai
UBS
UBS
$90
Buy
22.57%
Upside
Reiterated
05/08/26
Analyst Reiterates Buy on CG Oncology, Maintains $90 Price Target Ahead of Key Cretostimogene Data Readouts
Guggenheim Analyst forecast on CGON
Bradley Canino
Guggenheim
Guggenheim
$90
Buy
22.57%
Upside
Reiterated
02/27/26
Guggenheim Sticks to Its Buy Rating for CG Oncology, Inc. (CGON)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering CG Oncology, Inc.

3 Months
Alec StranahanBank of America Securities
Success Rate
9/11 ratings generated profit
82%
Average Return
+23.82%
Copying Alec Stranahan's trades and holding each position for 3 Months would result in 81.82% of your transactions generating a profit, with an average return of +23.82% per trade.
1 Year
Tyler Van BurenTD Cowen
Success Rate
11/11 ratings generated profit
100%
Average Return
+104.94%
Copying Tyler Van Buren's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +104.94% per trade.
2 Years
Tyler Van BurenTD Cowen
Success Rate
11/11 ratings generated profit
100%
Average Return
+129.92%
Copying Tyler Van Buren's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +129.92% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CGON Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
12
10
6
8
5
Buy
17
24
23
32
25
Hold
0
0
0
2
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
29
34
29
42
32
In the current month, CGON has received 30 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. CGON average Analyst price target in the past 3 months is 91.55.
Each month's total comprises the sum of three months' worth of ratings.

CGON Financial Forecast

CGON Earnings Forecast

Next quarter’s earnings estimate for CGON is -$0.66 with a range of -$0.73 to -$0.52. The previous quarter’s EPS was -$0.71. CGON beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year CGON has Performed in-line its overall industry.
Next quarter’s earnings estimate for CGON is -$0.66 with a range of -$0.73 to -$0.52. The previous quarter’s EPS was -$0.71. CGON beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year CGON has Performed in-line its overall industry.

CGON Sales Forecast

Next quarter’s sales forecast for CGON is $333.00K with a range of $0.00 to $1.21M. The previous quarter’s sales results were $1.08M. CGON beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year CGON has Performed in-line its overall industry.
Next quarter’s sales forecast for CGON is $333.00K with a range of $0.00 to $1.21M. The previous quarter’s sales results were $1.08M. CGON beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year CGON has Performed in-line its overall industry.

CGON Stock Forecast FAQ

What is CGON’s average 12-month price target, according to analysts?
Based on analyst ratings, CG Oncology, Inc.’s 12-month average price target is 91.55.
    What is CGON’s upside potential, based on the analysts’ average price target?
    CG Oncology, Inc. has 24.67% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is CGON a Buy, Sell or Hold?
          CG Oncology, Inc. has a consensus rating of Strong Buy which is based on 13 buy ratings, 1 hold ratings and 0 sell ratings.
            What is CG Oncology, Inc.’s price target?
            The average price target for CG Oncology, Inc. is 91.55. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $108.00 ,the lowest forecast is $80.00. The average price target represents 24.67% Increase from the current price of $73.43.
              What do analysts say about CG Oncology, Inc.?
              CG Oncology, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.
                How can I buy shares of CGON?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.